By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Markets > Stocks > Musk’s brain implant firm Neuralink valued at around $5 billion – Reuters
Stocks

Musk’s brain implant firm Neuralink valued at around $5 billion – Reuters

News Room
Last updated: 2023/06/05 at 1:16 PM
By News Room
Share
1 Min Read
SHARE

© Reuters.

Investing.com — Neuralink, the brain implant start-up owned by Elon Musk, is now worth around $5 billion, according to a Reuters report.

Citing five unnamed sources familiar with the matter, Reuters said that the valuation was based on privately executed stock trades. The sources added that the value of these shares was supported by purchases made by private investors ahead of a U.S. regulatory ruling in late May, Reuters noted.

On May 25, Neuralink announced that it was given the green light to conduct a trial with chips placed into human minds. However, the company has not yet received the go-ahead to use the product commercially.

In the wake of the trial’s approval, Neuralink shares privately were being offered to investors at a $7 billion valuation, or $55 a share, according to an email seen by Reuters.

Executives at Neuralink and Musk did not respond to request for comment from Reuters.

Read the full article here

News Room June 5, 2023 June 5, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data – Slideshow (NASDAQ:CRBP) 2025-12-11

This article was written byFollowSeeking Alpha's transcripts team is responsible for the…

Disney to invest $1bn into OpenAI

Stay informed with free updatesSimply sign up to the Artificial intelligence myFT…

Freedom for Venezuela coming ‘soon’, says opposition leader

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Netflix or Paramount? Hollywood shudders over Warner Bros Discovery sale

In the eyes of many in Hollywood, the battle for control of…

Why young grads are struggling to find jobs

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

CPS reports solid 2023 performance, eyes future growth By Investing.com

By News Room
Stocks

Niu Technologies faces mixed results in Q4 2023 By Investing.com

By News Room
Stocks

Exagen Inc. reports strong 2023 revenue growth By Investing.com

By News Room
Stocks

Legacy Housing reports mixed results amid sales decline By Investing.com

By News Room
Stocks

Harmony Biosciences exec sells over $383k in stock By Investing.com

By News Room
Stocks

Biofrontera posts record revenue and outlines growth plans By Investing.com

By News Room
Stocks

Granite Ridge CFO buys $31,000 in company stock By Investing.com

By News Room
Stocks

Coliseum Capital Management buys MasterCraft Boat shares worth over $3.2m By Investing.com

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?